References
  1. Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, and Nasrallah GK. Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene among Healthy Population: An Update. Frontiers in Oncology  2018;8:211.
  2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, et al. The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood  2016;127:2375–2390.
  3. Fernandez-Pol S, Silva O, and Natkunam Y. Defining the Elusive Boundaries of Chronic Active Epstein-Barr Virus Infection. Haematologica  2018;103: 924–927.
  4. Cohen JI. Optimal Treatment for Chronic Active Epstein-Barr Virus Disease. Pediatric Transplantation  2009;13:393–96.
  5. Roliński J, Grywalska E, Pyzik A, Dzik M, Opoka-Winiarska V, Surdacka A, Maj M, et al. Interferon Alpha as Antiviral Therapy in Chronic Active Epstein-Barr Virus Disease with Interstitial Pneumonia - Case Report. BMC Infectious Diseases  2018;18:190.
  6. Hongjun B, Xu L, Peng H, Lin Y, Li X, Wang H, and Qin Y. Chronic Active Epstein-Barr Virus Infection with Systemic Vasculitis and Pulmonary Arterial Hypertension in a Child. Frontiers in Pediatrics  2019;7:219.
  7. Tseng YJ, Ding WQ, Zhong L, Chen J, and Luo ZG. Chronic Active Epstein–Barr Virus (CAEBV) Enteritis. International Journal of Infectious Diseases  2019;82:15–17.
  8. Xiao HJ, Li J, Song HM, Li ZH, Dong M, and Zhou XG. Epstein–Barr Virus-Positive T/NK-Cell Lymphoproliferative Disorders Manifested as Gastrointestinal Perforations and Skin Lesions. Medicine2016;95:e2676.
  9. Cohen, JI, Manoli I, Dowdell K, Krogmann TA, Tamura D, Radecki P, Bu W, et al. Hydroa Vacciniforme–like Lymphoproliferative Disorder: An EBV Disease with a Low Risk of Systemic Illness in Whites. Blood  2019;133:2753–2764.
  10. Dávila Saldaña BJ, John T, Bonifant C, Buchbinder D, Chandra S, Chandrakasan S, Chang W, Chen L, et al. High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv  2022;6:452-459.
  11. Bollard CM and Cohen JI. How I Treat T-Cell Chronic Active Epstein-Barr Virus Disease. Blood  2018;131: 2899–2905.
  12. Dimitrova D, Gea-Banacloche J, Steinberg SM, Sadler JL, Hicks SN, Carroll E, Wilder JS, et al. Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases. Biology of Blood and Marrow Transplantation 2020;26:94–106.
  13. Gupta G, Man I, and Kemmett D. Hydroa Vacciniforme: A Clinical and Follow-up Study of 17 Cases. Journal of the American Academy of Dermatology  2000;42:208–213.
  14. Nitiyarom R, and Wongpraparut C. Hydroa Vacciniforme and Solar Urticaria. Dermatologic Clinics 2014;32:345–53.
  15. Hirai Y, Yamamoto T, Kimura H, Ito Y, Tsuji K, Miyake T, Morizane S, Suzuki D, Fujii K, and Iwatsuki K. Hydroa Vacciniforme Is Associated with Increased Numbers of Epstein–Barr Virus–Infected γδ T Cells. Journal of Investigative Dermatology  2012;132:1401–1408.
  16. Quintanilla-Martinez L, and Fend F. Deciphering Hydroa Vacciniforme. Blood  2019;133:2735–2737.
  17. Kimura H and Fujiwara S. Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases. Frontiers in Pediatrics  2019;6:417.
  18. Kawa K, Okamura T, Yasui M, Sato E, and Inoue M. Allogeneic Hematopoietic Stem Cell Transplantation for Epstein–Barr Virus-Associated T/NK-Cell Lymphoproliferative Disease. Critical Reviews in Oncology/Hematology  2002;44: 251–257.
  19. Sawada A and Inoue M. Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders. Frontiers in Pediatrics  2018;6:334.
  20. Guo N, Chen Y, Wang Y, Huang Y, Feng Y, Li M, and Rao H. Clinicopathological Categorization of Hydroa Vacciniforme-like Lymphoproliferative Disorder: An Analysis of Prognostic Implications and Treatment Based on 19 Cases. Diagnostic Pathology  2019;14:82.
  21. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, and Rooney CM. Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas. Immunosurveillance, Immunodeficiencies and Lymphoproliferations , 2002;159:123–133.
  22. Kim YJ, Choi SY, Lee WJ, Won CH, Chang SE, Choi JH, and Lee MW. Two Cases of Hydroa Vacciniforme-like Lymphoproliferative Disease Controlled by Anti-Inflammatory Agents. Photodermatology, Photoimmunology & Photomedicine  2017;33:287–290.
  23. Rodriguez-Pinilla SM, Barrionuevo C, Garcia J, Martinez MT, Pajares R, Montes-Moreno S, Casavilca S, et al. EBV-Associated Cutaneous NK/T-Cell Lymphoma. American Journal of Surgical Pathology  2010;34:1773–1782.
  24. Cohen J, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, et al. Characterization and Treatment of Chronic Active Epstein-Barr Virus Disease: A 28-Year Experience in the United States.Blood 2011;22:5835-5849.
  25. Sawada A, Inoue M, and Kawa K. How We Treat Chronic Active Epstein–Barr Virus Infection. International Journal of Hematology 2017;4:406-418.
  26. Kawa K, Sawada A, Sato M, Okamura T, Sakata N, Kondo O, Kimoto T, et al. Excellent Outcome of Allogeneic Hematopoietic SCT with Reduced-Intensity Conditioning for the Treatment of Chronic Active EBV Infection. Bone Marrow Transplantation  2010;46:77–83.
  27. Xiao H, Hu B, Luo R, Hu H, Zhang J, Kuang W, Zhang R, et al. Chronic active Epstein–Barr virus infection manifesting as coronary artery aneurysm and uveitis. Virol J 2020;17:166-175.
  28. Ba H, Xu L, Peng H, Lin Y, Li X, Wang H, and Qin Y. Chronic Active Epstein-Barr Virus Infection with Systemic Vasculitis and Pulmonary Arterial Hypertension in a Child. Frontiers in Pediatrics  2019;7:219.
  29. Murakami K, Ohsawa M, Hu SX, Kanno H, Aozasa K, and Nose M. Large-Vessel Arteritis Associated with Chronic Active Epstein-Barr Virus Infection. Arthritis & Rheumatism  1998;41:369–373.